288 related articles for article (PubMed ID: 33668876)
1. Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
Fuhr V; Vafadarnejad E; Dietrich O; Arampatzi P; Riedel A; Saliba AE; Rosenwald A; Rauert-Wunderlich H
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668876
[TBL] [Abstract][Full Text] [Related]
2. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
3. [scRNA-sequencing uncovers metabolism and CD52 as new targets in ibrutinib-surviving mantle cell lymphoma cells].
Fuhr V; Vafadarnejad E; Dietrich O; Arampatzi P; Riedel A; Saliba AE; Rosenwald A; Rauert-Wunderlich H
Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):31-35. PubMed ID: 36222922
[TBL] [Abstract][Full Text] [Related]
4. miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.
Yuan J; Zhang Q; Wu S; Yan S; Zhao R; Sun Y; Tian X; Zhou K
Exp Hematol; 2021 Nov; 103():52-59.e2. PubMed ID: 34474146
[TBL] [Abstract][Full Text] [Related]
5. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
Wu X; Nowakowski KE; Abeykoon JP; Manske M; Stenson MJ; Timm MM; Hanson CA; Van Dyke DL; Dasari S; Witzig TE
Eur J Haematol; 2021 Oct; 107(4):458-465. PubMed ID: 34214199
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma.
Hoang NM; Liu Y; Bates PD; Heaton AR; Lopez AF; Liu P; Zhu F; Chen R; Kondapelli A; Zhang X; Selberg PE; Ngo VN; Skala MC; Capitini CM; Rui L
Cell Rep Med; 2024 Apr; 5(4):101484. PubMed ID: 38554704
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Zhao X; Wang MY; Jiang H; Lwin T; Park PM; Gao J; Meads MB; Ren Y; Li T; Sun J; Fahmi NA; Singh S; Sehgal L; Wang X; Silva AS; Sotomayor EM; Shain KH; Cleveland JL; Wang M; Zhang W; Qi J; Shah BD; Tao J
Cell Rep; 2021 Mar; 34(11):108870. PubMed ID: 33730585
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma.
Wang L; Mo S; Li X; He Y; Yang J
Cancer Biol Med; 2020 Aug; 17(3):726-739. PubMed ID: 32944402
[No Abstract] [Full Text] [Related]
9. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma.
Liu Y; Kimpara S; Hoang NM; Daenthanasanmak A; Li Y; Lu L; Ngo VN; Bates PD; Song L; Gao X; Bebel S; Chen M; Chen R; Zhang X; Selberg PE; Kenkre VP; Waldmann TA; Capitini CM; Rui L
Blood; 2023 Nov; 142(22):1879-1894. PubMed ID: 37738652
[TBL] [Abstract][Full Text] [Related]
10. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Cinar M; Hamedani F; Mo Z; Cinar B; Amin HM; Alkan S
Leuk Res; 2013 Oct; 37(10):1271-7. PubMed ID: 23962569
[TBL] [Abstract][Full Text] [Related]
11. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
[TBL] [Abstract][Full Text] [Related]
12. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
13. [Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Vorobyev VI; Gemdzhian EG; Fedorova LV; Mikhailova NB; Ilyasov RK; Kaleikina LP; Trubyakova OS; Kaplanov KD; Melnichenko EV; Martynova EV; Yakovleva EP; Li OY; Tarasenko EV; Chumakova EP; Bulieva NB; Nesterova ES; Margolin OV; Zherebtsova VA; Butaev LS; Ptushkin VV
Ter Arkh; 2021 Jul; 93(7):770-777. PubMed ID: 36286727
[TBL] [Abstract][Full Text] [Related]
14. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
Guan J; Huang D; Yakimchuk K; Okret S
Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
[TBL] [Abstract][Full Text] [Related]
15. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
[TBL] [Abstract][Full Text] [Related]
16. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
Li Y; Bouchlaka MN; Wolff J; Grindle KM; Lu L; Qian S; Zhong X; Pflum N; Jobin P; Kahl BS; Eickhoff JC; Wuerzberger-Davis SM; Miyamoto S; Thomas CJ; Yang DT; Capitini CM; Rui L
Oncogene; 2016 Dec; 35(48):6223-6234. PubMed ID: 27157620
[TBL] [Abstract][Full Text] [Related]
17. Targeting protein kinase C in mantle cell lymphoma.
Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
[TBL] [Abstract][Full Text] [Related]
18. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
Zhang L; Yao Y; Zhang S; Liu Y; Guo H; Ahmed M; Bell T; Zhang H; Han G; Lorence E; Badillo M; Zhou S; Sun Y; Di Francesco ME; Feng N; Haun R; Lan R; Mackintosh SG; Mao X; Song X; Zhang J; Pham LV; Lorenzi PL; Marszalek J; Heffernan T; Draetta G; Jones P; Futreal A; Nomie K; Wang L; Wang M
Sci Transl Med; 2019 May; 11(491):. PubMed ID: 31068440
[TBL] [Abstract][Full Text] [Related]
19. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Okahashi N; Uchihara M; Hoshino E
Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
Maruyama D; Omi A; Nomura F; Touma T; Noguchi Y; Takebe K; Izutsu K
Int J Hematol; 2024 Feb; 119(2):146-155. PubMed ID: 38195971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
